相似文献
1
Augmented therapeutic efficacy of irinotecan is associated with enhanced drug accumulation.
Cancer Lett. 2011 Dec 8;311(2):219-29. doi: 10.1016/j.canlet.2011.07.023. Epub 2011 Aug 6.
2
Potentiation of irinotecan sensitivity by Se-methylselenocysteine in an in vivo tumor model is associated with downregulation of cyclooxygenase-2, inducible nitric oxide synthase, and hypoxia-inducible factor 1alpha expression, resulting in reduced angiogenesis.
Oncogene. 2006 Apr 20;25(17):2509-19. doi: 10.1038/sj.onc.1209073.
3
Hypoxia-specific drug tirapazamine does not abrogate hypoxic tumor cells in combination therapy with irinotecan and methylselenocysteine in well-differentiated human head and neck squamous cell carcinoma a253 xenografts.
Neoplasia. 2008 Aug;10(8):857-65. doi: 10.1593/neo.08424.
4
Irinotecan pharmacokinetic and pharmacogenomic alterations induced by methylselenocysteine in human head and neck xenograft tumors.
Mol Cancer Ther. 2005 May;4(5):843-54. doi: 10.1158/1535-7163.MCT-04-0315.
5
Se-methylselenocysteine sensitizes hypoxic tumor cells to irinotecan by targeting hypoxia-inducible factor 1alpha.
Cancer Chemother Pharmacol. 2010 Oct;66(5):899-911. doi: 10.1007/s00280-009-1238-8. Epub 2010 Jan 12.
6
Selective modulation of the therapeutic efficacy of anticancer drugs by selenium containing compounds against human tumor xenografts.
Clin Cancer Res. 2004 Apr 1;10(7):2561-9. doi: 10.1158/1078-0432.ccr-03-0268.
7
Efficacy of increasing the therapeutic index of irinotecan, plasma and tissue selenium concentrations is methylselenocysteine dose dependent.
Biochem Pharmacol. 2007 May 1;73(9):1280-7. doi: 10.1016/j.bcp.2006.12.020. Epub 2006 Dec 22.
8
Selenium protects against toxicity induced by anticancer drugs and augments antitumor activity: a highly selective, new, and novel approach for the treatment of solid tumors.
Clin Colorectal Cancer. 2005 Jul;5(2):132-5. doi: 10.3816/ccc.2005.n.026.
9
Tumor vascular maturation and improved drug delivery induced by methylselenocysteine leads to therapeutic synergy with anticancer drugs.
Clin Cancer Res. 2008 Jun 15;14(12):3926-32. doi: 10.1158/1078-0432.CCR-08-0212.
10
Antitumor activity of IHL-305, a novel pegylated liposome containing irinotecan, in human xenograft models.
Oncol Rep. 2012 Jan;27(1):189-97. doi: 10.3892/or.2011.1465. Epub 2011 Sep 20.
引用本文的文献
1
Selenium compounds for cancer prevention and therapy - human clinical trial considerations.
Med Rev (2021). 2025 Jan 6;5(3):203-230. doi: 10.1515/mr-2024-0065. eCollection 2025 Jun.
2
Phase I Clinical Trial of High Doses of Seleno-L-methionine in Combination with Axitinib in Patients with Previously Treated Metastatic Clear-cell Renal Cell Carcinoma.
Clin Cancer Res. 2025 Apr 1;31(7):1204-1211. doi: 10.1158/1078-0432.CCR-24-3234.
3
Druggable Biomarkers Altered in Clear Cell Renal Cell Carcinoma: Strategy for the Development of Mechanism-Based Combination Therapy.
Int J Mol Sci. 2023 Jan 4;24(2):902. doi: 10.3390/ijms24020902.
4
Potential Role of Selenium in the Treatment of Cancer and Viral Infections.
Int J Mol Sci. 2022 Feb 17;23(4):2215. doi: 10.3390/ijms23042215.
5
Non-Coding Micro RNAs and Hypoxia-Inducible Factors Are Selenium Targets for Development of a Mechanism-Based Combination Strategy in Clear-Cell Renal Cell Carcinoma-Bench-to-Bedside Therapy.
Int J Mol Sci. 2018 Oct 29;19(11):3378. doi: 10.3390/ijms19113378.
6
Selenium targets resistance biomarkers enhancing efficacy while reducing toxicity of anti-cancer drugs: preclinical and clinical development.
Oncotarget. 2018 Jan 23;9(12):10765-10783. doi: 10.18632/oncotarget.24297. eCollection 2018 Feb 13.
7
Selenium compounds, apoptosis and other types of cell death: an overview for cancer therapy.
Int J Mol Sci. 2012;13(8):9649-9672. doi: 10.3390/ijms13089649. Epub 2012 Aug 2.
本文引用的文献
1
Tumor vascular maturation and improved drug delivery induced by methylselenocysteine leads to therapeutic synergy with anticancer drugs.
Clin Cancer Res. 2008 Jun 15;14(12):3926-32. doi: 10.1158/1078-0432.CCR-08-0212.
2
Irinotecan pharmacokinetic and pharmacogenomic alterations induced by methylselenocysteine in human head and neck xenograft tumors.
Mol Cancer Ther. 2005 May;4(5):843-54. doi: 10.1158/1535-7163.MCT-04-0315.
3
Lack of microvessels in well-differentiated regions of human head and neck squamous cell carcinoma A253 associated with functional magnetic resonance imaging detectable hypoxia, limited drug delivery, and resistance to irinotecan therapy.
Clin Cancer Res. 2004 Dec 1;10(23):8005-17. doi: 10.1158/1078-0432.CCR-04-1306.
4
Selective modulation of the therapeutic efficacy of anticancer drugs by selenium containing compounds against human tumor xenografts.
Clin Cancer Res. 2004 Apr 1;10(7):2561-9. doi: 10.1158/1078-0432.ccr-03-0268.
5
Therapeutic synergy between irinotecan and 5-fluorouracil against human tumor xenografts.
Clin Cancer Res. 2004 Feb 1;10(3):1121-9. doi: 10.1158/1078-0432.ccr-0913-3.
6
Lessons learned from the irinotecan metabolic pathway.
Curr Med Chem. 2003 Jan;10(1):41-9. doi: 10.2174/0929867033368619.
7
Lessons from basic research in selenium and cancer prevention.
J Nutr. 1998 Nov;128(11):1845-54. doi: 10.1093/jn/128.11.1845.
8
Simple and versatile high-performance liquid chromatographic method for the simultaneous quantitation of the lactone and carboxylate forms of camptothecin anticancer drugs.
J Chromatogr B Biomed Sci Appl. 1997 Mar 28;691(1):161-71. doi: 10.1016/s0378-4347(96)00426-4.
9
Irinotecan (CPT-11): a brief overview.
Clin Exp Pharmacol Physiol. 1996 Oct-Nov;23(10-11):1000-4. doi: 10.1111/j.1440-1681.1996.tb01158.x.
10
Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), by human liver carboxylesterase.
Biochem Pharmacol. 1996 Oct 11;52(7):1103-11. doi: 10.1016/0006-2952(96)00457-1.
Zotero 插件